Xiao et al. proved that the naturally-modified molecule EZH2 can lower PD-L1 expression by directly upregulating the levels of the promoter H3K27me3 in HCC, providing a promising strategy for HCC immunotherapy [30]. The gene discussed is EZH2; the disease is hepatocellular carcinoma.